Lubiprostone: a novel treatment for chronic constipation

Brian E Lacy, L Campbell Levy, Brian E Lacy, L Campbell Levy

Abstract

Chronic constipation is highly prevalent, reduces patients' quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue ofprostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.

Figures

Figure 1
Figure 1
Structure of lubiprostone.

References

    1. Amitiza® Package Insert.

    1. Brandt LJ, Prather CM, Quigley EMM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100:S5–S22.
    1. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290:G942–G7.
    1. Cash BD, Lacy BE. Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterol Hepatol. 2006;2:736–49.
    1. Chen TY. Structure and function of ClC channels. Annu Rev Physiol. 2005;67:809–39.
    1. Crawford DF, Perentesis GP, Engelke KJ, et al. Effects of lubiprostone, a novel GI chloride channel activator, on reproductive and developmental toxicity endpoints in rats. Am J Gastroenterol. 2005;100:S331.
    1. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287:C1173–C83.
    1. Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23:461–7.
    1. DiPalma JA, Cleveland MV, McGowan J, et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436–41.
    1. Drossman DA, Chey WD, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double blind trials. Gastroenterol. 2007;132:2586–7.
    1. Grider JR, Jin JG. Distinct populations of sensory neurons mediate the peristaltic reflex elicited by muscle stretch and mucosal stimulation. J Neurosci. 1994;14:2854–60.
    1. Higgins PDR, Johanson JF. Epidemiology of chronic constipation in North America: A systematic review. Am J Gastroenterol. 2004;99:750–9.
    1. Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol. 2002;97:1986–93.
    1. Johanson JF, Gargano MA, Holland PC, et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterol. 2004;126:A298. Abstract 749.
    1. Johanson JF, Gargano MA, Holland PC, et al. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week Phase III study. Am J Gastroenterol. 2005a;100:A884.
    1. Johanson JF, Gargano MA, Holland PC, et al. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primacy efficacy. Am J Gastroenterol. 2005b;100:A896.
    1. Johanson JF, Morton D, Geenan J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–7.
    1. Johanson JF, Panas R, Holland PC, et al. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterol. 2006a;130:A317.
    1. Johanson JF, Panas R, Holland PC, et al. A dose-ranging, double-blind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (IBS-C) Gastroenterol. 2006b;130:A25.
    1. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351–61.
    1. Lacy BE, Cole MS. Constipation in the older adult. Clinical Geriatr. 2004;12:44–54.
    1. Lipecka J, Bali M, Thomas A, et al. Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol. 2002;282:C805–C16.
    1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.
    1. Mindell JA, Maduke M. ClC chloride channels. Genome Bio. 2001;2:3003.1–3003.6.
    1. Muller-Lissner SA, Kamm MA, Scarpignato C, et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100:232–42.
    1. Perentesis GP, Crawford DF, Engelke KJ, et al. Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle. Am J Gastroenterol. 2005;100:A900.
    1. Rivera E, Wahle A, Joswick TR, et al. Lubiprostone, a novel type-2 chloride channel (Clc-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation. Gastroenterol. 2007;132:A191–2.
    1. Sprenger C, Copa A, Morganroth J, et al. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiogram results. Gastroenterol. 2007;132:A325.
    1. Suzuki M, Morita T, Iwamoto T. Diversity of Cl channels. Cell Mol Life Sci. 2006;63:12–24.
    1. Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol. 1992;136:165–77.
    1. Ueno R. Multiple, escalating, oral-dose study to assess the safety, tolerance, and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol Motil. 2005;17:626.
    1. Ueno R, Hiroyoshi O, Engelke KJ. Effect of lubiprostone on morphine-induced constipation and analgesia. Gastroenterol. 2006d;130:A373–4.
    1. Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs. female subjects. Gastroenterol. 2006a;130:A322.
    1. Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs. non- elderly subjects. Gastroenterol. 2006b;130:A189.
    1. Ueno R, Osama H, Habe T, et al. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterol. 2004;126:A298.
    1. Ueno R, Panas R, Wahle A, et al. Long-term efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterol. 2006c;130:A188.
    1. Young RJ, Beerman LE, Vanderhoof JA. Increasing oral fluids in chronic constipation in children. Gastroenterol Nurs. 1998;21:156–61.
    1. Zelnorm (tegaserod maleate) Information. FDA/Center for Drug Evaluation and Research. 2007. Accessed September 27, 2007. URL:

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner